Adult mainstream STS · Desmoid+Phyllodes · Pediatric RMS — three-bucket stratification × 6 NCCN subtypes × 42 landmark trials indexed against a guideline-anchored timeline. Dual Brain Lab MVP 12.
From ABC-02 GemCis one-size-fits-all to RAGNAR / TRIDENT-1 eight-lane precision — the evolution and 2026 decision landscape of 39 landmark BTC trials cited by NCCN Biliary Tract Cancers V1.2026, fully PMID-traceable
From MIOS 1986 MAP chemo backbone to IDH1 / denosumab / PDGFR rare-subtype precision breakthroughs + IO failure across all subtypes — tracing the evolution of 35 bone sarcoma landmark trials cited by NCCN Bone V2.2026 and the 2026 decision landscape, fully PMID-traceable
HR+/HER2- · HER2+ · HER2-low · TNBC — four-subtype stratification × five paradigm shifts (foundation · anti-HER2 · CDK4/6 · ADC reshaping · IO breakthrough) — 86 landmark trials indexed against a guideline-anchored timeline. Dual Brain Lab MVP 11.
From the 1990s 5-FU backbone to 2025 BREAKWATER / CheckMate-8HW — tracing the evolution of 74 CRC landmark trials cited by NCCN Colon + NCCN Rectal, the metastatic → adjuvant extrapolation trap, and the MSI-H / BRAF / HER2 / KRAS G12C precision rockets — every PMID traceable.
From RTOG 85-01's counterintuitive definitive-CRT 50 Gy dose ceiling, to CROSS establishing neoadjuvant CRT, to the East Asian split (NEOCRTEC5010 / JCOG1109), to the advanced-IO big three (CheckMate-648 / KEYNOTE-590 / ESCORT-1st), to CheckMate-577 perioperative adjuvant — tracing the evolution of 42 landmark trials across the ESCC / EAC dual track and the 2026 decision landscape, with every PMID traceable
From INT-0116 adjuvant chemoRT to MATTERHORN perioperative IO, tracing the evolution of 58 landmark GC/GEJ trials cited by NCCN + CSCO 2025 into the 2026 decision landscape — East–West perioperative divergence + HER2 10-year leap + CLDN18.2 new subtype, all PMID-traceable
From SHARP sorafenib's 10-year solo run to the IMbrave150 / HIMALAYA / CARES-310 four-way IO combination standoff to the zero-biomarker dilemma — tracing the evolution of 42 HCC landmark trials cited in NCCN Hepatobiliary V1.2026 and the 2026 current decision landscape, all PMID-traceable
From INT-0099 CCRT to the three-arrow PD-1 convergence: the evolution and 2026 decision landscape of 23 NPC landmark trials cited by NCCN Cancer of the Nasopharynx V1.2026 — every PMID traceable
From TURRISI 1999 LS-SCLC chemoradiation, through IMpower133 IO breakthrough, to DeLLphi-301 DLL3 BiTE — mapping the evolution and 2026 decision landscape of 30 landmark trials cited by NCCN SCLC V1.2026, fully PMID-traceable